Multi-Agency Nanotech Toxicity Initiative Funded At $105.9 Mil. In FY 2004
This article was originally published in The Gray Sheet
Executive Summary
FDA will continue to monitor potential safety threats associated with some nanotechnology drug delivery devices, according to FDA Associate Commissioner for Science Norris Alderson, PhD
You may also be interested in...
Nanotech Safety, Efficacy Models Exist, But Nomenclature Problematic – FDA
FDA expects nanotechnology will be subject to the same efficacy standards demanded of medical devices, according to CDRH Office of Science & Engineering Laboratories Director Larry Kessler
Nanotech Safety, Efficacy Models Exist, But Nomenclature Problematic – FDA
FDA expects nanotechnology will be subject to the same efficacy standards demanded of medical devices, according to CDRH Office of Science & Engineering Laboratories Director Larry Kessler
EPA, FDA Agreements Aim To Clear Up Burdensome Regulatory Environment
Complex, overlapping federal regulations potentially are blocking availability of innovative disinfectants for medical uses, speakers at a recent Food & Drug Law Institute meeting suggested